Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study

• Published in: Osteoporosis international 2013-02, Vol.24 (2), p.489-494
• Main Authors: Garnero, P., Sornay-Rendu, E., Munoz, F., Borel, O., Chapurlat, R. D.
• Format: Article
• Language: English
• Subjects: 25-Hydroxyvitamin D; Adult; Age; Aged; Aged, 80 and over; Biomarkers - blood; Bone density; Bone Density - physiology; Bone mineral density; Bone Morphogenetic Proteins - blood; Bone Remodeling - physiology; Bone turnover; Collagen; Collagen (type I); Dual energy X-ray absorptiometry; Endocrinology; Enzyme-linked immunosorbent assay; Estradiol; Female; Follow-Up Studies; Fractures; France - epidemiology; Genetic Markers; Glycoproteins; Hip; Hormones; Humans; Medicine; Medicine & Public Health; Menopause; Middle Aged; Original Article; Orthopedics; Osteocytes; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - epidemiology; Osteoporosis, Postmenopausal - physiopathology; Osteoporotic Fractures - blood; Osteoporotic Fractures - epidemiology; Osteoporotic Fractures - physiopathology; Parathyroid hormone; Parathyroid Hormone - blood; Post-menopause; Rheumatology; Risk assessment; Risk Assessment - methods; Risk factors; SOST protein; Spine; Testosterone; Women
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-012-1978-x

Summary Sclerostin is a key regulator of bone formation. In a population of 572 postmenopausal women (mean age, 67 years) followed prospectively for a median of 6 years, there was no significant association between baseline levels of serum sclerostin and incidence of all fractures which occurred in 64 subjects. Introduction Sclerostin, an osteocyte soluble factor, is a major negative regulator of osteoblastic activity. Circulating sclerostin levels were reported to increase with age and to be modestly associated with bone mineral density (BMD) and bone turnover, but there are no data on the association with fracture risk. Methods We investigated 572 postmenopausal women (mean age, 67 ± 8.5 years) from the OFELY population-based cohort. The associations of serum sclerostin measured with a new two-site ELISA and spine and hip BMD by DXA, serum β-isomerized C-terminal crosslinking of type I collagen (CTX), intact N-terminal propeptide of type I collagen (PINP), intact PTH, 25-hydroxyvitamin D [25(OH)D], estradiol, testosterone, and fracture risk were analyzed. At the time of sclerostin measurements, 98 postmenopausal women had prevalent fractures. After a median of 6 years (interquartile range, 5–7 years) follow-up, 64 postmenopausal sustained an incident fracture. Results Serum sclerostin correlated positively with spine ( r  = 0.35, p